Health Care & Hospital Law
Nov. 5, 2011
Drugmakers rely on First Amendment
GlaxoSmithKline PLC will spend $3 billion to resolve a federal investigation into off-label drug marketing and other alleged fraud, but other pharmaceutical companies and individuals are fighting off-label cases with the First Amendment.
Daily Journal Staff Writer
While GlaxoSmithKline PLC announced Thursday that it will spend $3 billion to resolve an investigation into off-label drug marketing and other alleged fraud, other pharmaceutical companies and individuals are using their money to fight off-label cases with the First Amendment.
In the ongoing appeal of his conviction for wire fraud related to off-label marketing, Los Angeles-based lawyers for W. Scott...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In